This changed in 2012 as FDA approved a new multi-targeted, tyrosine kinase inhibitor, ponatinib (5), which possesses an imidazo[1,2-b]pyridazine moiety, for the treatment of chronic myeloid leukemia (CML).9 Ponatinib (5) is a third generation kinase inhibitor that overcomes the T3151 mutation and has potent inhibitory effect against BCR-ABL1 kinases and numerous ABL1 mutations. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.